Blogs | Law Meets Science
FDA Requires Drug Manufacturers to Update Prescribing Information for Opioid Pain Medicines
Oct 02 2025
Contributors
An audio summary of this article is available in the player below. Scroll to keep reading.
Listen and subscribe to Womble Perspectives wherever you get your podcasts.
This article was co-authored by Katie Clowers (Research Consultant at Womble Bond Dickinson).
On July 31, 2025, the U.S. Food and Drug Administration announced new safety labeling changes for all opioid pain medications to highlight the risks associated with long-term use. The updates emphasize potential misuse, addiction, overdose, and serious side effects. For drug manufacturers, this means updating product labeling to help patients, medical doctors, pharmacists, and other healthcare providers better understand the benefit-risk profile of opioid pain medicines when prescribed long term.
Among other things, the updated FDA guidelines stress a gradual tapering method when discontinuing opioids to reduce dangerous side effects associated with withdrawal. As background, one of the most critical physiological considerations surrounding prescription opioid use is the development of physical tolerance and dependence through neuroadaptation of mu-opioid receptors. Binding of opioids to their respective receptors in the brain reduces pain and produces feelings of euphoria by altering neurotransmitter release. In response to continued opioid exposure, the body attempts to restore normal physiological conditions by reducing receptor sensitivity and increasing activity of neurons that release excitatory neurotransmitters. In subsequent opioid use, their suppressive effect is counteracted by higher baseline levels of excitatory neurotransmitters, leading to diminished felt effects. If opioid use is abruptly discontinued, the resulting symptoms reflect the rebound activity of these neurotransmitters that were suppressed during opioid use. These symptoms can include, but are not limited to, generalized autonomic dysfunction, neuropsychiatric and cardiovascular effects.
Alongside tapering guidance, the new FDA guidelines identify naloxone and other opioid antagonists, which can reverse an opioid overdose within minutes. Respiratory depression, a leading cause of overdose-related fatalities, occurs when opioids bind to mu-opioid receptors in the areas of the brainstem responsible for maintaining respiration rate. By competitively binding these receptors, naloxone and other overdose reversal agents block the effect of opioids and restore physiological breathing rates.
The new labeling guidelines have also strengthened warnings about prescription drug interactions, particularly with gabapentinoids, which can significantly increase the risk of overdose. The pharmacokinetic pathways of opioids and gabapentinoids converge on the areas of the brainstem that regulate breathing. When taken together, opioids and gabapentinoids can act synergistically, depressing the central nervous system and dramatically increasing the risk of respiratory failure.
Besides the acute risks of opioid use, long-term use carries lesser-known consequences including alterations of enteric nervous system function. Over time, opioids can increase esophageal sphincter tone and reduce peristaltic activity, leading to decreased esophageal motility and transit time. The resulting clinical manifestations can include dysphagia and gastroesophageal reflux disease. (Babaei A, et al. 2019) The revised labeling guidelines recognize these gastrointestinal effects and stress the importance of monitoring and managing opioid-induced GI dysfunction.
In sum, the FDA’s updated opioid labeling changes illustrate how evolving science shapes legal responsibility and redefines the landscape in which patients, providers, and manufacturers operate. The complex physiological effects of opioid use underscore the critical need for further research into how different types of opioids impact risk across different patient populations. As scientific understanding evolves, so too must the legal and regulatory frameworks that govern opioid use to ensure that policies remain evidence-driven and grounded in the most current knowledge of patient safety.
